1-(3-氯-2-吡嗪)-4-甲基哌嗪 | 313657-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氯-2-吡嗪)-4-甲基哌嗪
• 中文别名: 2-氯-3-(4-甲基哌嗪-1-基)吡嗪
• 英文名称: 2-chloro-3-(4-methylpiperazin-1-yl)pyrazine
• 英文别名: 1-(3-chloro-2-pyrazinyl)-4-methylpiperazine
• CAS: 313657-05-5
• 化学式: C₉H₁₃ClN₄
• 分子量: 212.682
• InChiKey: QKGVXLAHFBSFHO-UHFFFAOYSA-N

物化性质

• 沸点：
  317.3±42.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(3-氯-2-吡嗪)-4-甲基哌嗪 以 2-羟基甲基-1,4-苯二恶 为溶剂， 以87%的产率得到2,3-Dihydro-1,4-benzodioxin-2-ylmethyl 3-(4-methyl-1-piperazinyl)-2-pyrazinyl Ether, Dihydrochloride
  参考文献：
  名称：

  Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

  摘要：

  通式（I）的化合物： 其中变量如规范中定义的那样，对于预防或治疗人类或动物中与血清素相关，特别是5-HT2受体相关的疾病是有用的，特别是与5-HT2c受体相关的疾病，尤其是与进食障碍、记忆障碍、精神分裂症、情绪障碍、焦虑障碍、疼痛、性功能障碍和尿液障碍等疾病相关的疾病。

  公开号：

  US06465467B1
• 作为产物：
  描述：

  N-甲基哌嗪 、 2,3-二氯吡嗪 在 magnesium sulfate 、 silica gel 作用下， 以 乙腈 为溶剂， 反应 60.0h， 以to give 10.7 g (75%) of the title compound as an oil that的产率得到1-(3-氯-2-吡嗪)-4-甲基哌嗪
  参考文献：
  名称：

  Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

  摘要：

  本发明涉及公式（I）的化合物：其中Ar是可选取代的芳基或杂芳基；A是（i）-O-，-S-，-SO2-，-NH-，（ii）C1-4烷基或C1-6酰基取代的氮原子或（iii）C1-8烷基链或具有2至8个链原子的杂烷基链，可选地含有至少一个不饱和度，并且可以取代和/或包含桥以形成具有3-8个环成员的饱和或部分或完全不饱和的环；B是-C（R4）（R5）-，-OC（R4）（R5）-，-N（R6）C（R4）（R5）-，-N（R6）-，-O-，-S-或-SO2-；R是可选的取代C3-8环烷基，芳基或杂芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或饱和的二氮杂环或氨基二氮杂环，其具有4至7个环成员，或饱和的氨基氮杂双环，氮杂双环或二氮杂双环，其具有7至10个环成员，这些环可选地在一个或多个位置上取代，或者是一个组-[C（R4）（R5）]xN（R2a）（R3a）]；其中，R2a，R3a，R4，R5，R6和x如权利要求书中所定义，n为0或1；以及其药学上可接受的盐，水合物和前药形式。这些化合物可以通过自身常规方法制备，并可用于治疗患有血清素相关疾病的人类或动物，例如进食障碍，尤其是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑症，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含公式（I）化合物的制药组合物。

  公开号：

  US07071180B2

文献信息

• [EN] NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS<br/>[FR] NOUVEAUX DERIVES DE PIPERAZINYL-PYRAZINONE POUR LE TRAITEMENT DES TROUBLES LIES AU RECEPTEUR 5-HT2A
  申请人：BIOVITRUM AB

  公开号：WO2004009586A1

  公开（公告）日：2004-01-29

  Compounds of the general formula (I): (I)wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.

  通式（I）的化合物：（I）其中m、n、R1、R2、R3和R4如规范中所述。还包括包含这些化合物的药物组合物，它们的制备方法，以及利用这些化合物制备用于治疗5-HT2A受体相关疾病或医疗状况的药物的用途。
• [EN] NOVEL COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS EN TANT QUE MODULATEURS DE ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2017021879A1

  公开（公告）日：2017-02-09

  The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R1, R2, R3, R4, R5, Ra, Rb, n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

  本公开涉及式(I)的化合物及其药用盐，其中环A、环B、L、R1、R2、R3、R4、R5、Ra、Rb、n、m、p和q如本文所定义，这些化合物作为视黄酸相关孤儿受体γt（RORγt）调节剂具有活性。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗RORγt介导的疾病、紊乱、综合症或症状方面具有用处，例如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化症、牛皮癣、神经退行性疾病和癌症。
• CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES
  申请人：Biovitrum, AB, a Stockholm, Sweden corporation

  公开号：US20040242554A1

  公开（公告）日：2004-12-02

  The invention relates to compounds of the general formula (I): 1 wherein Ar is optionally substituted aryl or heteroaryl; A is (i) —O—, —S—, —SO 2 —, —NH—, (ii) a C 1-4 -alkyl- or C 1-6 -acyl-substituted nitrogen atom or (iii) a C 1-8 -alkylene chain or a heteroalkylene chain having 2 to 8 chain atoms, which optionally contains at least one unsaturation, and which may be substituted and/or contain a bridge to form a saturated or partially or fully unsaturated ring having 3-8 ring members; B is —C(R 4 )(R 5 )—, —OC(R 4 )(R 5 )—, —N(R 6 )C(R 4 )(R 5 )—, —N(R 6 )—, —O—, —S— or —SO 2 —; R is optionally substituted C 3-8 -cycloalkyl, aryl or heteroaryl; R 1 is (i) a saturated or unsaturated azacyclic or aminoazacyclic ring, or a saturated diazacyclic or aminodiazacyclic ring, which has 4 to 7 ring members, or a saturated aminoazabicyclic, azabicyclic or diazabicyclic ring which has 7 to 10 ring members, which rings optionally are substituted in one or more positions, or a group —[C(R 4 )(R 5 )] x N(R 2a )(R 3a )]; R 2a , R 3a , R 4 , R 5 , R 6 and x are as defined in the claims, and n is 0 or 1; and pharmaceutically acceptable salts, hydrates and prodrug forms thereof. The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory, disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).

  本发明涉及通式（I）的化合物：其中Ar是可选取代的芳基或杂芳基；A是（i）—O—，—S—，—SO2—，—NH—，（ii）C1-4烷基或C1-6酰基取代的氮原子，或（iii）C1-8烷基链或具有2-8链原子的杂烷基链，其可选包含至少一个不饱和度，并且可以取代和/或含有桥接以形成具有3-8环成员的饱和或部分或完全不饱和环；B是—C（R4）（R5）—，—OC（R4）（R5）—，—N（R6）C（R4）（R5）—，—N（R6）—，—O—，—S—或—SO2—；R是可选取代的C3-8环烷基，芳基或杂芳基；R1是（i）饱和或不饱和的氮杂环或氨基氮杂环，或饱和的二氮杂环或氨基二氮杂环，其具有4-7环成员，或饱和的氨基氮杂双环、氮杂双环或二氮杂双环，其具有7-10环成员，这些环在一个或多个位置上可选取代，或者是一个组—[C（R4）（R5）]xN（R2a）（R3a）；R2a，R3a，R4，R5，R6和x如权利要求中所定义，n为0或1；以及其药学上可接受的盐、水合物和前药形式。这些化合物可以通过常规方法制备，并可用于治疗患有血清素相关疾病的人或动物，例如进食障碍，尤其是肥胖症，记忆障碍，精神分裂症，情绪障碍，焦虑障碍，疼痛，性功能障碍和泌尿系统疾病。本发明还涉及这种用途以及包含通式（I）化合物的制药组合物。
• Compounds
  申请人：——

  公开号：US20040063693A1

  公开（公告）日：2004-04-01

  Compounds of the general formula (I): 1 wherein m, n, R 1 , R 2 , R 3 and R 4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT 2A receptor-related disorders or medical conditions.

  通式（I）的化合物：其中m，n，R1，R2，R3和R4如说明书所述。还包括包含这些化合物的制药组合物，它们的制备过程，以及使用这些化合物制备治疗5-HT2A受体相关疾病或医疗条件的药物的方法。
• Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones
  申请人：Biovitrum AB

  公开号：US07244722B2

  公开（公告）日：2007-07-17

  Compounds of the general formula (I): wherein m, n, R1, R2, R3 and R4 are as described in the specification. Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament for the treatment of 5-HT2A receptor-related disorders or medical conditions.

  通式（I）的化合物，其中m，n，R1，R2，R3和R4如规范中所述。此外还包括包含这些化合物的制药组合物，它们的制备过程，以及这些化合物用于制备用于治疗5-HT2A受体相关疾病或医疗状况的药物的用途。